PetMeds reported a 19.9% net sales fall and lower cash. Simparica TRIO received FDA emergency authorization to treat screwworm in dogs, while language models missed cases surgeons classified for surgery. This edition also covers IDEXX’s planned Cancer Dx additions, Battery Ventures’ Vetspire investment and copyright suits alleging unlicensed image use by veterinary practices.
Two US practice data samples showed more revenue while visit, client, invoice or patient counts fell. US pet insurers wrote more direct premiums in 2025; Merck and Hill’s global sales rose in the second quarter. American Regent recalled 2 Adequan Canine lots after it found glass fibers.
CVS pages conflicted on pet-prescription availability, and Texas added three screwworm zones and revised Zone 14.A. This edition also covers FDA animal-drug manufacturing incentives, Four Corners’ purchase of 102 Mission-operated properties, and Virbac companion animal growth alongside lower total North American revenue.
